NASDAQ:FNCH

Finch Therapeutics Group Competitors

$13.02

+0.98 (+8.14 %)

(As of 05/18/2021 03:45 AM ET)

Add

Compare

Today's Range

$12.62

▼

$13.36

50-Day Range

$12.03

▼

$17.51

52-Week Range

$11.56

▼

$22.50

Volume1,428 shs

Average Volume141,292 shs

Market Capitalization$613.83 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Finch Therapeutics Group (NASDAQ:FNCH) Vs. NUVB, SEER, IBRX, IMCR, BCAB, and EWTX

Should you be buying FNCH stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Finch Therapeutics Group, including Nuvation Bio (NUVB), Seer (SEER), ImmunityBio (IBRX), Immunocore (IMCR), BioAtla (BCAB), and Edgewise Therapeutics (EWTX).

Finch Therapeutics Group vs. Nuvation Bio Stock

Finch Therapeutics Group (NASDAQ:FNCH) and Nuvation Bio (NYSE:NUVB) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, valuation, institutional ownership, earnings and dividends.

Profitability

This table compares Finch Therapeutics Group and Nuvation Bio's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Finch Therapeutics Group	N/A	N/A	N/A
Nuvation Bio	N/A	N/A	N/A

Earnings & Valuation

This table compares Finch Therapeutics Group and Nuvation Bio's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Finch Therapeutics Group	N/A	N/A	N/A	N/A	N/A
Nuvation Bio	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent ratings for Finch Therapeutics Group and Nuvation Bio, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Finch Therapeutics Group	0	0	3	0	3.00
Nuvation Bio	0	0	6	0	3.00

Finch Therapeutics Group presently has a consensus price target of $29.3333, indicating a potential upside of 125.29%. Nuvation Bio has a consensus price target of $17.40, indicating a potential upside of 46.10%. Given Finch Therapeutics Group's higher probable upside, research analysts clearly believe Finch Therapeutics Group is more favorable than Nuvation Bio.

Finch Therapeutics Group vs. Seer Stock

Finch Therapeutics Group (NASDAQ:FNCH) and Seer (NASDAQ:SEER) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, valuation, institutional ownership, earnings and dividends.

Profitability

This table compares Finch Therapeutics Group and Seer's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Finch Therapeutics Group	N/A	N/A	N/A
Seer	N/A	N/A	N/A

Earnings & Valuation

This table compares Finch Therapeutics Group and Seer's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Finch Therapeutics Group	N/A	N/A	N/A	N/A	N/A
Seer	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent ratings for Finch Therapeutics Group and Seer, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Finch Therapeutics Group	0	0	3	0	3.00
Seer	0	2	2	0	2.50

Finch Therapeutics Group presently has a consensus price target of $29.3333, indicating a potential upside of 125.29%. Seer has a consensus price target of $66.3333, indicating a potential upside of 115.23%. Given Finch Therapeutics Group's stronger consensus rating and higher probable upside, research analysts clearly believe Finch Therapeutics Group is more favorable than Seer.

Summary

Finch Therapeutics Group beats Seer on 3 of the 3 factors compared between the two stocks.

Finch Therapeutics Group vs. ImmunityBio Stock

ImmunityBio (NASDAQ:IBRX) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.

Profitability

This table compares ImmunityBio and Finch Therapeutics Group's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ImmunityBio	N/A	N/A	N/A
Finch Therapeutics Group	N/A	N/A	N/A

Valuation and Earnings

This table compares ImmunityBio and Finch Therapeutics Group's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	N/A	N/A	N/A	N/A	N/A
Finch Therapeutics Group	N/A	N/A	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for ImmunityBio and Finch Therapeutics Group, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	0	0	1	0	3.00
Finch Therapeutics Group	0	0	3	0	3.00

ImmunityBio presently has a consensus target price of $25.00, indicating a potential upside of 51.98%. Finch Therapeutics Group has a consensus target price of $29.3333, indicating a potential upside of 125.29%. Given Finch Therapeutics Group's higher possible upside, analysts clearly believe Finch Therapeutics Group is more favorable than ImmunityBio.

Summary

Finch Therapeutics Group beats ImmunityBio on 2 of the 2 factors compared between the two stocks.

Finch Therapeutics Group vs. Immunocore Stock

Immunocore (NASDAQ:IMCR) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.

Profitability

This table compares Immunocore and Finch Therapeutics Group's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Immunocore	N/A	N/A	N/A
Finch Therapeutics Group	N/A	N/A	N/A

Valuation and Earnings

This table compares Immunocore and Finch Therapeutics Group's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	N/A	N/A	N/A	N/A	N/A
Finch Therapeutics Group	N/A	N/A	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Immunocore and Finch Therapeutics Group, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	0	1	2	0	2.67
Finch Therapeutics Group	0	0	3	0	3.00

Immunocore presently has a consensus target price of $54.3333, indicating a potential upside of 44.89%. Finch Therapeutics Group has a consensus target price of $29.3333, indicating a potential upside of 125.29%. Given Finch Therapeutics Group's stronger consensus rating and higher possible upside, analysts clearly believe Finch Therapeutics Group is more favorable than Immunocore.

Summary

Finch Therapeutics Group beats Immunocore on 3 of the 3 factors compared between the two stocks.

Finch Therapeutics Group vs. BioAtla Stock

BioAtla (NASDAQ:BCAB) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.

Profitability

This table compares BioAtla and Finch Therapeutics Group's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	N/A	N/A
Finch Therapeutics Group	N/A	N/A	N/A

Valuation and Earnings

This table compares BioAtla and Finch Therapeutics Group's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	N/A	N/A	N/A	N/A	N/A
Finch Therapeutics Group	N/A	N/A	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for BioAtla and Finch Therapeutics Group, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	0	0	4	0	3.00
Finch Therapeutics Group	0	0	3	0	3.00

BioAtla presently has a consensus target price of $62.75, indicating a potential upside of 37.01%. Finch Therapeutics Group has a consensus target price of $29.3333, indicating a potential upside of 125.29%. Given Finch Therapeutics Group's higher possible upside, analysts clearly believe Finch Therapeutics Group is more favorable than BioAtla.

Finch Therapeutics Group vs. Edgewise Therapeutics Stock

Edgewise Therapeutics (NASDAQ:EWTX) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.

Profitability

This table compares Edgewise Therapeutics and Finch Therapeutics Group's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	N/A	N/A
Finch Therapeutics Group	N/A	N/A	N/A

Valuation and Earnings

This table compares Edgewise Therapeutics and Finch Therapeutics Group's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	N/A	N/A	N/A
Finch Therapeutics Group	N/A	N/A	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Edgewise Therapeutics and Finch Therapeutics Group, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	0	1	3	0	2.75
Finch Therapeutics Group	0	0	3	0	3.00

Edgewise Therapeutics presently has a consensus target price of $34.25, indicating a potential upside of 27.32%. Finch Therapeutics Group has a consensus target price of $29.3333, indicating a potential upside of 125.29%. Given Finch Therapeutics Group's stronger consensus rating and higher possible upside, analysts clearly believe Finch Therapeutics Group is more favorable than Edgewise Therapeutics.

Summary

Finch Therapeutics Group beats Edgewise Therapeutics on 2 of the 2 factors compared between the two stocks.